Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27663024 | 0.82 | CYP2D6 (0.46) | MAPK14GRM5NPC1RAB9ACYP2D6 | |
| SCHEMBL29462011 | 0.80 | KMO (0.67) | KMOBCHEACHEIDO1METAP2 | |
| SCHEMBL2126795 | 0.80 | KMO (0.67) | KMOBCHEACHEIDO1METAP2 | |
| SCHEMBL14425914 | 0.79 | GRM5 (0.50) | KMOMAPK14GRM5CYP2D6 | |
| SCHEMBL14425577 | 0.79 | KMO (0.51) | KMOMAPK14GRM5CYP2D6 | |
| SCHEMBL21742566 | 0.78 | GRM5 (0.43) | MAPK14GRM5CYP2D6 | |
| SCHEMBL5444466 | 0.78 | MAPK14 (0.45) | KMOMAPK14IDO1METAP2 | |
| SCHEMBL14519516 | 0.78 | EGFR (0.63) | MAPK14IDO1METAP2 | |
| SCHEMBL7672405 | 0.78 | GRM5 (0.49) | MAPK14GRM5IDO1METAP2NPC1 | |
| SCHEMBL20566349 | 0.78 | HSD17B1 (0.58) | GRM5METAP2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3503240-A1 | ORGANIC SEMICONDUCTOR LAYER | Novaled GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| US-9716233-B2 | Electronic device including a fluoranthene derivative | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| CN-104650117-A | Organic compound and application thereof in organic electroluminescence devices | BEIJING ETERNAL MATERIAL TECHNOLOGY CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | KMO 3581/4885MAPK14 1962/4885GRM5 3144/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | KMO 3581/4885MAPK14 1962/4885GRM5 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.